Zanubrutinib for the treatm... - Researchers

Zanubrutinib for the treatment of MYD88 wild-type Waldenstrï¿½m macroglobulinemia: a substudy of the phase 3 ASPEN trial

Citation

Dimopoulos, M, Garcia-Sanz, R, Lee, H et al. 2020, 'Zanubrutinib for the treatment of MYD88 wild-type Waldenstrï¿½m macroglobulinemia: a substudy of the phase 3 ASPEN trial', Blood Advances, vol. 4, no. 23, pp. 6009-6018.

Year

2020

ANU Authors

Professor Dipti Talaulikar

Updated: 05 July 2024 / Responsible Officer: Director (Research Services Division) / Page Contact: Researchers